CA2527112C - 2-aminobenzoyl derivatives as nmda receptor antagonists - Google Patents

2-aminobenzoyl derivatives as nmda receptor antagonists Download PDF

Info

Publication number
CA2527112C
CA2527112C CA2527112A CA2527112A CA2527112C CA 2527112 C CA2527112 C CA 2527112C CA 2527112 A CA2527112 A CA 2527112A CA 2527112 A CA2527112 A CA 2527112A CA 2527112 C CA2527112 C CA 2527112C
Authority
CA
Canada
Prior art keywords
disorders
alkyl
hydrogen
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2527112A
Other languages
English (en)
French (fr)
Other versions
CA2527112A1 (en
Inventor
Nava Zisapel
Moshe Laudon
Dvorah Daily
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of CA2527112A1 publication Critical patent/CA2527112A1/en
Application granted granted Critical
Publication of CA2527112C publication Critical patent/CA2527112C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
CA2527112A 2003-06-26 2004-06-24 2-aminobenzoyl derivatives as nmda receptor antagonists Expired - Fee Related CA2527112C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL156669 2003-06-26
IL15666903A IL156669A0 (en) 2003-06-26 2003-06-26 2-aminobenzoyl derivatives
PCT/IL2004/000567 WO2004112690A2 (en) 2003-06-26 2004-06-24 2-aminobenzoyl derivatives

Publications (2)

Publication Number Publication Date
CA2527112A1 CA2527112A1 (en) 2004-12-29
CA2527112C true CA2527112C (en) 2012-08-21

Family

ID=32587677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2527112A Expired - Fee Related CA2527112C (en) 2003-06-26 2004-06-24 2-aminobenzoyl derivatives as nmda receptor antagonists

Country Status (31)

Country Link
US (1) US8309767B2 (cg-RX-API-DMAC7.html)
EP (1) EP1644316B1 (cg-RX-API-DMAC7.html)
JP (1) JP4646907B2 (cg-RX-API-DMAC7.html)
KR (1) KR101115196B1 (cg-RX-API-DMAC7.html)
CN (1) CN1835910B (cg-RX-API-DMAC7.html)
AR (1) AR044786A1 (cg-RX-API-DMAC7.html)
AT (1) ATE460391T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004249012B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0411382A (cg-RX-API-DMAC7.html)
CA (1) CA2527112C (cg-RX-API-DMAC7.html)
CY (1) CY1110043T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004025937D1 (cg-RX-API-DMAC7.html)
DK (1) DK1644316T3 (cg-RX-API-DMAC7.html)
EA (1) EA011255B1 (cg-RX-API-DMAC7.html)
ES (1) ES2341958T3 (cg-RX-API-DMAC7.html)
HN (1) HN2004000224A (cg-RX-API-DMAC7.html)
IL (1) IL156669A0 (cg-RX-API-DMAC7.html)
IS (1) IS8235A (cg-RX-API-DMAC7.html)
MX (1) MXPA06000022A (cg-RX-API-DMAC7.html)
NO (1) NO20060420L (cg-RX-API-DMAC7.html)
NZ (1) NZ544908A (cg-RX-API-DMAC7.html)
PA (1) PA8605401A1 (cg-RX-API-DMAC7.html)
PE (1) PE20050230A1 (cg-RX-API-DMAC7.html)
PL (1) PL1644316T3 (cg-RX-API-DMAC7.html)
PT (1) PT1644316E (cg-RX-API-DMAC7.html)
SI (1) SI1644316T1 (cg-RX-API-DMAC7.html)
TW (1) TWI342210B (cg-RX-API-DMAC7.html)
UA (1) UA85187C2 (cg-RX-API-DMAC7.html)
UY (1) UY28382A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004112690A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600640B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1869002A (zh) * 2005-05-27 2006-11-29 中国科学院上海药物研究所 一类非甾体雄激素受体调节剂、其制备方法和用途
US7622495B2 (en) * 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
WO2016027757A1 (ja) * 2014-08-18 2016-02-25 国立大学法人大阪大学 新規2-アミノベンゾイル誘導体
JP6836044B2 (ja) * 2015-03-05 2021-02-24 国立大学法人 東京医科歯科大学 長期記憶誘導剤
US11712425B2 (en) 2018-03-14 2023-08-01 Albert Einstein College Of Medicine Immunoregulatory role of 3-OH-kynurenamine and uses thereof
US11911376B2 (en) 2020-03-30 2024-02-27 The Regents Of The University Of Colorado Methods for preventing and treating retinal damage
WO2026004785A1 (ja) * 2024-06-25 2026-01-02 ロート製薬株式会社 組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT305987B (de) 1969-12-18 1973-03-26 Degussa Verfahren zur Herstellung von neuen Aminoketonen
GB1334884A (en) * 1970-12-18 1973-10-24 Sumitomo Chemical Co Aminoalcohols and their conversion to aminoketones
JPS5336455B2 (cg-RX-API-DMAC7.html) * 1973-02-03 1978-10-03
US4018823A (en) * 1976-04-20 1977-04-19 Morton-Norwich Products, Inc. 4',5'-Dimethoxy-2',3-diaminopropiophenone dihydrochloride
FR2569185B1 (fr) * 1984-08-20 1986-09-05 Lafon Labor Derives de 1-(aminophenyl)-2-amino-ethanone, procede de preparation et utilisation en therapeutique

Also Published As

Publication number Publication date
EA011255B1 (ru) 2009-02-27
AU2004249012B2 (en) 2010-04-01
EP1644316B1 (en) 2010-03-10
PL1644316T3 (pl) 2010-08-31
EA200600115A1 (ru) 2008-06-30
NZ544908A (en) 2009-11-27
ZA200600640B (en) 2007-05-30
UY28382A1 (es) 2004-11-08
PE20050230A1 (es) 2005-04-22
TWI342210B (en) 2011-05-21
JP4646907B2 (ja) 2011-03-09
WO2004112690B1 (en) 2005-05-19
TW200503672A (en) 2005-02-01
KR20060023581A (ko) 2006-03-14
MXPA06000022A (es) 2006-07-06
EP1644316A4 (en) 2006-10-25
UA85187C2 (en) 2009-01-12
KR101115196B1 (ko) 2012-02-24
AR044786A1 (es) 2005-10-05
US8309767B2 (en) 2012-11-13
PT1644316E (pt) 2010-06-02
HK1094795A1 (en) 2007-04-13
CN1835910B (zh) 2010-09-29
ATE460391T1 (de) 2010-03-15
JP2007518673A (ja) 2007-07-12
NO20060420L (no) 2006-01-25
WO2004112690A3 (en) 2005-03-17
WO2004112690A2 (en) 2004-12-29
IS8235A (is) 2006-01-16
CN1835910A (zh) 2006-09-20
BRPI0411382A (pt) 2006-09-19
PA8605401A1 (es) 2006-03-24
DE602004025937D1 (de) 2010-04-22
IL156669A0 (en) 2004-01-04
DK1644316T3 (da) 2010-07-19
CY1110043T1 (el) 2015-01-14
SI1644316T1 (sl) 2010-06-30
HN2004000224A (es) 2007-12-21
ES2341958T3 (es) 2010-06-30
CA2527112A1 (en) 2004-12-29
US20060270733A1 (en) 2006-11-30
AU2004249012A1 (en) 2004-12-29
EP1644316A2 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
Chiarugi et al. Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase
JP2025102814A (ja) 発毛を調節するための組成物及び方法
US7622495B2 (en) Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
JP2001515483A (ja) 抗てんかん誘発剤
AU2004249012B2 (en) 2-aminobenzoyl derivatives
EP1263425B1 (en) Use of comt inhibitors as analgesics
WO2010016939A1 (en) Hypoglycemic dihydropyridones
JP2007506435A (ja) 神経ペプチドff受容体2アゴニストによる神経因性疼痛の処置
JP2007518673A5 (cg-RX-API-DMAC7.html)
HK1094795B (en) 2-aminobenzoyl derivatives
RU2180657C1 (ru) Анилид n-(3'-хлорбутен-2'-ил)антраниловой кислоты, проявляющий противовоспалительную и анальгетическую активности
JP2005509673A (ja) 新規な医薬化合物
KR100267708B1 (ko) Nmda 수용체 길항제로 작용하는 4-(3-치환-2-옥소및2-티옥소-1,3-옥사졸리딘-5-일메톡시)-퀴놀린-2-카복실산 유도체
CA3124820A1 (en) Compositions and methods for modulating hair growth
Clark et al. Pharmacology of GABA transporters
NZ759233B2 (en) Compositions and methods for modulating hair growth

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180626